What To Know
- “We are excited that MEG will allow the University of Florida to potentially create a new standard of clinical care for patients, and to expand the research capabilities for neuroscientists, and widen the field of Magnetoencephalography,” concluded John Fulford, Managing Director, MEGIN OY.
- The Norman Fixel Institute plans to use MEGIN's non-invasive MEG technology for both clinical services and research initiatives and will immediately utilize MEG for brain mapping in epilepsy and brain tumor patients.
MEGIN announced the sale of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, to the Norman Fixel Institute for Neurological Diseases at University of Florida Health (UF Health). The Norman Fixel Institute coordinates the efforts of clinicians, researchers and therapists from different fields such as aging, bioengineering, communication sciences, computer science, health psychology, internal medicine, neurology, neuroscience, neurosurgery, occupational therapy, physical medicine and kinesiology, physical therapy, radiology, rehabilitation science and speech therapy. UF Health’s patient-centric approach provides access to interdisciplinary, comprehensive care and research.
MEGIN’s TRIUX™ neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with exquisite resolution. The TRIUX™ neo offers the most precise functional information currently available on the market for functional brain imaging in children, adolescents and adults.
The Norman Fixel Institute plans to use MEGIN’s non-invasive MEG technology for both clinical services and research initiatives and will immediately utilize MEG for brain mapping in epilepsy and brain tumor patients. MEG will also assist UF investigators in performing translational research in a wider variety of neurological diseases as well as advance basic neuroscience research across the entire UF campus.
“We are excited that MEG will allow the University of Florida to potentially create a new standard of clinical care for patients, and to expand the research capabilities for neuroscientists, and widen the field of Magnetoencephalography,” concluded John Fulford, Managing Director, MEGIN OY.
